Drug industry anxious about scrapping price regulation scheme

BMJ 2008; 336 doi: 10.1136/bmj.39526.738345.DB (Published 27 March 2008)
Cite this as: BMJ 2008;336:686.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Andrew Cole
  1. 1London

    Almost half (46%) of the United Kingdom’s drug companies expect to cut back on clinical trials in the coming year because of continued uncertainty about future arrangements for pricing drugs.

    In a survey of more than 100 companies earlier this month on behalf of the Association of the British Pharmaceutical Industry and the Confederation of British Industry three quarters said they had little confidence in the current UK market environment, and 83% expected things to get worse in the next year.

    The survey also showed that 30% of drug companies expect to cut staff in the next year, and more than …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL